Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Benzinga Newsdesk